Yamazaki N, Shimizu A, Ozaki M, Hamada M, et al. Real-world safety and effectiveness of pembrolizumab in Japanese patients with
radically unresectable melanoma: An all-case postmarketing surveillance in Japan. J Dermatol 2022 Jul 27. doi: 10.1111/1346-8138.16518.
PMID: 35896505